New drug PLB-002 targets Hard-to-Treat cancers in early trial
NCT ID NCT07304128
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This early-stage study tests a new drug called PLB-002 in about 100 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. PLB-002 is designed to attack cancer cells while sparing healthy ones.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center- Gynecology Onc
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Email: •••••@•••••
-
Fudan University Shanghai Cancer Center- Phase 1
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.